ArticleEpilepsia2026
Modeling temporal lobe epilepsy with hippocampal sclerosis in rats using the selective neurotoxin stable substance P-saporin.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTemporal lobe epilepsy with hippocampal sclerosis (TLE-HS+) is a common and often refractory form of human epilepsy. In the hippocampus, the neurotoxin stable substance P-saporin (SSP-SAP) targets hilar inhibitory interneurons and has been used to determine whether hilar neuron loss in an otherwise normal brain is sufficient to initiate the epileptogenic process. We determined the time course of SSP-SAP-induced epileptogenesis, as well as the loss of principal cells and astrogliosis, two defining features of TLE-HS+.
methodsWe started with 70-day-old male and female Sprague Dawley rats and injected SSP-SAP into four unilateral sites along the longitudinal axis of the rat dentate gyrus. We determined how long SSP-SAP is detectably present in inhibitory interneurons and then analyzed the electroencephalographic characteristics and behavioral expression of the "reactive" seizures that developed several days after SSP-SAP injection. We then quantified the number of self-generated 7-Hz epileptiform events over 3 months. Finally, we counted the numbers of principal cells and astrocytes up to 2 months postinjection.
resultsSSP-SAP was internalized within 2 h after injection and was immunocytochemically undetectable by 5 days. Rats exhibited spontaneous electrographic and behavioral reactive seizures between days 4 and 6 after SSP-SAP injection, with most seizures having a Racine score of either 1 or 2. After the early seizures had abated, the number and duration of self-generated 7-Hz epileptiform events, which were associated with behavioral arrest, progressively increased over the 3-month observation period, indicating epileptogenesis. We also observed the progressive loss of CA1 and CA3 neurons and the progressive increase in astrocytes over time, two defining features of HS, a common pathological observation in TLE patients. SIGNIFICANCE: This study confirms that the SSP-SAP model reproduces the defining features of human TLE and that a primary, selective, and longitudinally extensive γ-aminobutyric acidergic defect is sufficient to trigger epileptogenesis that results in TLE-HS+.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.